Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Purpose: The novel topoisomerase I inhibitor karenitecin (KTN) shows activity against melanoma. We examined whether histone deacetylase inhibition could potentiate the DNA strand cleavage, cytotoxicity as well as the clinical toxicity, and efficacy of KTN in melanoma. Experimental Design: Apoptosis, COMET, and xenograft experiments were carried out as described previously. A phase I/II trial of valproic acid (VPA) and KTN was conducted in patients with stage IV melanoma, with any number of prior therapies, Eastern Cooperative Oncology Group performance status 0-2, and adequate organ function. Results: VPA pretreatment potentiated KTN-induced apoptosis in multiple melanoma cell lines and in mouse A375 xenografts. VPA increased KTN-induced DNA strand breaks. In the phase I/II trial, 39 patients were entered, with 37 evaluable for toxicity and 33 evaluable for response. Somnolence was the dose-limiting toxicity. The maximum tolerated dose for VPA was 75 mg/kg/d; at maximum tolerated dose, serum VPA was ∼200 μg/mL (1.28 mmol/L). At the dose expansion cohort, 47% (7 of 15) of patients had stable disease; median overall survival and time to progression were 32.8 and 10.2 weeks, respectively. Histone hyperacetylation was observed in peripheral blood mononuclear cells at maximum tolerated dose. Conclusion: VPA potentiates KTN-induced DNA strand breaks and cytotoxicity. VPA can be combined at 75 mg/kg/d for 5 days with full-dose KTN without overlapping toxicities. In metastatic poor prognosis melanoma, this combination is associated with disease stabilization in 47% of patients. Further testing of this combination appears warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Comet Assay for DNA Damage and Repair: Principles, Applications, and Limitations
Collins, A. R. (2004) · Molecular Biotechnology · doi:10.1385/mb:26:3:249 · Cited by 2,892
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999) · Nature · doi:10.1038/43710 · Cited by 1,714
Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors
Khan, N., Jeffers, M., Kumar, S., Hackett, C., Boldog, F., Khramtsov, N., Qian, X., Mills, E., Berghs, S. C., Carey, N., et al. (2008) · Biochemical Journal · doi:10.1042/bj20070779 · Cited by 713
Cited by
Molecular and Therapeutic Potential and Toxicity of Valproic Acid
Chateauvieux, S., Morceau, F., Dicato, M., & Diederich, M. (2010) · Journal of Biomedicine and Biotechnology · doi:10.1155/2010/479364 · Cited by 512
HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications
Khan, O., & La Thangue, N. B. (2012) · Immunology & Cell Biology · doi:10.1038/icb.2011.100 · Cited by 450
“125 Unfortunately, other combination clinical trials in solid tumors have proven to have no efficacy including two small clinical trials in colorectal cancer of 5-fluorouracil and vorinostat, a trial of the topoisomerase II inhibitor kareniticin and vorinostat in metastatic melanoma and a trial of valproate, followed…”
BackgroundHistone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
Wagner, J. M., Hackanson, B., Lübbert, M., & Jung, M. (2010) · Clinical Epigenetics · doi:10.1007/s13148-010-0012-4 · Cited by 338
Interplay between epigenetics and metabolism in oncogenesis: mechanisms and therapeutic approaches
Wong, C. C., Qian, Y., & Yu, J. (2017) · Oncogene · doi:10.1038/onc.2016.485 · Cited by 262
Trials with ‘epigenetic’ drugs: An update
Nebbioso, A., Carafa, V., Benedetti, R., & Altucci, L. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.09.004 · Cited by 237
“…al., 2007; Stamatopoulos et al., 2009), AML and myelodysplastic syndromes (MDS) in combination with 5-azacytidine (Kuendgen et al., 2011), mela- noma (Daud et al., 2009), HIV infection (Archin et al., 2010), au- toimmune lymphoproliferative syndrome (ALPS) (Dowdell et al., 2009), human…”
Metadata
- Authors
- Daud, A. I., Dawson, J., DeConti, R. C., Bicaku, E., Marchion, D., Bastien, S., Hausheer, F. A., Lush, R., Neuger, A., Sullivan, D. M., & Munster, P. N.
- Venue
- Clinical Cancer Research
- Published
- 2009-04-01
- Volume
- 15
- Issue
- 7
- Pages
- 2479-2487
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2140103101
- Cited by
- 86
- References
- 3
- FWCI
- 3.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-08-1931
- The paper
- Daud, A. I., Dawson, J., DeConti, R. C., Bicaku, E., Marchion, D., Bastien, S., Hausheer, F. A., Lush, R., Neuger, A., Sullivan, D. M., & Munster, P. N. (2009). Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-08-1931
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.